CY1121517T1 - Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib - Google Patents

Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib

Info

Publication number
CY1121517T1
CY1121517T1 CY20191100382T CY191100382T CY1121517T1 CY 1121517 T1 CY1121517 T1 CY 1121517T1 CY 20191100382 T CY20191100382 T CY 20191100382T CY 191100382 T CY191100382 T CY 191100382T CY 1121517 T1 CY1121517 T1 CY 1121517T1
Authority
CY
Cyprus
Prior art keywords
antibodies
fucucylized
fgfr2iiib
enanti
fucosylated
Prior art date
Application number
CY20191100382T
Other languages
English (en)
Inventor
Thomas Harding
Kristen Pierce
Namrata Patil
Thomas Brennan
Julie Hambleton
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of CY1121517T1 publication Critical patent/CY1121517T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα εφεύρεση παρέχει αντισώματα που δεσμεύουν FGFR2lllb, όπου τα αντισώματα είναι μη φουκοζυλιωμένα. Η παρούσα εφεύρεση παρέχει συνθέσεις που περιλαμβάνουν αντισώματα που δεσμεύουν FGFR2lllb, όπου τουλάχιστον 95% των αντισωμάτων στη σύνθεση είναι μη φουκοζυλιωμένα. Σε μερικές υλοποιήσεις, παρέχονται μέθοδοι αγωγής του καρκίνου που περιλαμβάνουν χορήγηση μη φουκοζυλιωμένων αντισωμάτων έναντι-FGFR2IIID.
CY20191100382T 2013-08-01 2019-04-05 Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib CY1121517T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361861198P 2013-08-01 2013-08-01
US201361901732P 2013-11-08 2013-11-08
US201461933632P 2014-01-30 2014-01-30
PCT/US2014/049008 WO2015017600A1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies

Publications (1)

Publication Number Publication Date
CY1121517T1 true CY1121517T1 (el) 2020-05-29

Family

ID=51358085

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100382T CY1121517T1 (el) 2013-08-01 2019-04-05 Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib

Country Status (31)

Country Link
US (4) US20150050273A1 (el)
EP (3) EP4036118A1 (el)
JP (4) JP6860342B2 (el)
KR (2) KR102516152B1 (el)
CN (2) CN112225810A (el)
AU (3) AU2014296174B2 (el)
CA (1) CA2915665C (el)
CL (2) CL2016000221A1 (el)
CY (1) CY1121517T1 (el)
DK (2) DK3708583T3 (el)
ES (2) ES2913291T3 (el)
HK (1) HK1220211A1 (el)
HR (1) HRP20190502T1 (el)
HU (2) HUE058243T2 (el)
IL (1) IL243409B (el)
LT (2) LT3027651T (el)
ME (1) ME03476B (el)
MX (2) MX2016001236A (el)
MY (1) MY184628A (el)
NZ (1) NZ715201A (el)
PE (2) PE20160190A1 (el)
PH (2) PH12016500137A1 (el)
PL (2) PL3708583T3 (el)
PT (2) PT3027651T (el)
RS (1) RS58719B1 (el)
RU (2) RU2740714C2 (el)
SG (1) SG11201600767UA (el)
SI (2) SI3708583T1 (el)
TW (2) TWI633120B (el)
WO (1) WO2015017600A1 (el)
ZA (1) ZA201603218B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4036118A1 (en) 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
EP3066469B1 (en) * 2013-11-05 2017-10-11 Roche Diagnostics GmbH A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
RU2021107536A (ru) * 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
SG10202112636SA (en) * 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
WO2019040780A1 (en) * 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
CA3091174A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
WO2019165075A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody dosing regimens
BR112020017925A2 (pt) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. Anticorpos contra b7-h4 e métodos de uso dos mesmos
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
AU2019361923A1 (en) 2018-10-15 2021-06-03 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2020410863A1 (en) * 2019-12-24 2022-06-23 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-FGFR2b antibodies
AR120883A1 (es) * 2019-12-24 2022-03-23 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
US20230052680A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
TW202241951A (zh) * 2020-12-29 2022-11-01 大陸商深圳福沃藥業有限公司 抗ｆｇｆｒ２抗體及其用途
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA2063431C (en) 1989-07-06 2002-10-29 Lewis T. Williams Receptors for fibroblast growth factors
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
CN101357943A (zh) * 2001-10-25 2009-02-04 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE502646T1 (de) 2002-01-31 2011-04-15 Max Planck Gesellschaft Fgfr agoniste
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
CA2766627C (en) * 2003-05-02 2019-12-03 Xencor, Inc. Optimized fc variants and methods for their generation
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
SI1678314T1 (sl) 2003-10-22 2013-01-31 Keck Graduate Institute Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
JP2008528033A (ja) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス， インコーポレイテッド ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
US8207303B2 (en) * 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2007134210A2 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
EP2035034A4 (en) * 2006-06-09 2009-11-18 Univ Maryland GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
AU2007315211B2 (en) 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
US20090068110A1 (en) 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2119780B1 (en) 2007-01-24 2015-03-25 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
AU2008230880B2 (en) 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
EP2142569A2 (en) * 2007-03-28 2010-01-13 Biogen Idec, Inc. Non-fucosylated antibodies
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US8688158B2 (en) 2008-03-26 2014-04-01 Nec Corporation Radio resource control method, radio station apparatus, recording medium storing radio station control program, and radio communication system
CA2727247A1 (en) * 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
ES2523740T3 (es) 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
US9096877B2 (en) * 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
CA2777068C (en) * 2009-10-14 2020-05-26 Kalobios Pharmaceuticals, Inc. Antibodies to epha3
EP2523679A4 (en) 2010-01-14 2013-07-24 Univ Yale Inc RECEPTORT SYROSINE KINASE (RTK) INHIBITOR AND ITS USE METHOD
EP2547698B1 (en) 2010-03-14 2015-07-29 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
MX2012013068A (es) 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anticuerpos anti - fgfr2.
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103201287B (zh) 2010-08-12 2016-04-13 艾托生物有限公司 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US9228023B2 (en) * 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US20150023989A1 (en) 2011-12-14 2015-01-22 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof
PT2831110T (pt) * 2012-03-30 2018-09-28 Univ California Terapia anti-emp2 reduz as células-tronco do cancro
US9714298B2 (en) 2012-04-09 2017-07-25 Daiichi Sankyo Company, Limited Anti-FGFR2 antibodies and methods of use thereof for treating cancer
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JPWO2014007369A1 (ja) 2012-07-05 2016-06-02 国立研究開発法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
JP2016526016A (ja) 2013-05-01 2016-09-01 ファイヴ プライム セラピューティクス インク がんを治療する方法
JP6696896B2 (ja) 2013-06-13 2020-05-20 ユニバーシティ オブ サウス オーストラリアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈ Ａｕｓｔｒａｌｉａ 前立腺癌を検出する方法
EP4036118A1 (en) 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015210886A1 (en) 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
RU2021107536A (ru) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака

Also Published As

Publication number Publication date
PH12016500137B1 (en) 2016-04-18
US20220168416A1 (en) 2022-06-02
TWI679021B (zh) 2019-12-11
TW201536804A (zh) 2015-10-01
TW201906629A (zh) 2019-02-16
US20160339100A1 (en) 2016-11-24
CA2915665C (en) 2020-07-28
RU2019125027A3 (el) 2020-02-28
IL243409B (en) 2019-10-31
NZ715201A (en) 2021-12-24
PE20210949A1 (es) 2021-05-24
KR20160030578A (ko) 2016-03-18
JP2023018049A (ja) 2023-02-07
EP4036118A1 (en) 2022-08-03
HK1220211A1 (zh) 2017-04-28
US20190175730A1 (en) 2019-06-13
ZA201603218B (en) 2019-03-27
IL243409A0 (en) 2016-03-31
AU2021245169A1 (en) 2021-11-04
PL3027651T3 (pl) 2019-08-30
CA2915665A1 (en) 2015-02-05
SG11201600767UA (en) 2016-03-30
AU2014296174A1 (en) 2016-01-21
CN105452296B (zh) 2020-09-25
AU2019206039A1 (en) 2019-08-01
EP3708583A1 (en) 2020-09-16
PL3708583T3 (pl) 2022-06-06
EP3708583B1 (en) 2022-03-02
KR102516152B1 (ko) 2023-03-31
US11235059B2 (en) 2022-02-01
DK3708583T3 (da) 2022-05-16
HRP20190502T1 (hr) 2019-05-03
RS58719B1 (sr) 2019-06-28
KR20230047508A (ko) 2023-04-07
EP3027651A1 (en) 2016-06-08
PH12019501393A1 (en) 2020-09-14
PH12016500137A1 (en) 2016-04-18
DK3027651T3 (en) 2019-04-15
JP2020040955A (ja) 2020-03-19
US20150050273A1 (en) 2015-02-19
CN105452296A (zh) 2016-03-30
RU2698061C2 (ru) 2019-08-21
WO2015017600A1 (en) 2015-02-05
MY184628A (en) 2021-04-10
PT3708583T (pt) 2022-05-13
SI3027651T1 (sl) 2019-05-31
RU2016106101A (ru) 2017-09-06
ES2913291T3 (es) 2022-06-01
JP2016527273A (ja) 2016-09-08
JP6860342B2 (ja) 2021-04-14
CL2018002291A1 (es) 2018-09-14
US10172937B2 (en) 2019-01-08
MX2020009223A (es) 2020-10-14
LT3708583T (lt) 2022-04-11
HUE043815T2 (hu) 2019-09-30
EP3027651B1 (en) 2019-02-27
ME03476B (me) 2020-01-20
JP2022078080A (ja) 2022-05-24
AU2014296174B2 (en) 2019-05-02
PE20160190A1 (es) 2016-04-28
BR112015032789A2 (pt) 2017-11-07
TWI633120B (zh) 2018-08-21
RU2740714C2 (ru) 2021-01-20
SI3708583T1 (sl) 2022-05-31
ES2719103T3 (es) 2019-07-08
AU2019206039B2 (en) 2021-07-08
PT3027651T (pt) 2019-05-31
LT3027651T (lt) 2019-04-10
HUE058243T2 (hu) 2022-07-28
RU2019125027A (ru) 2019-08-19
CN112225810A (zh) 2021-01-15
JP7183136B2 (ja) 2022-12-05
MX2016001236A (es) 2016-05-24
CL2016000221A1 (es) 2016-07-08

Similar Documents

Publication Publication Date Title
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
CY1119567T1 (el) Θεραπευτικα πεπτιδια
EA201590987A1 (ru) Соединения и способы их применения
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
EA201590997A1 (ru) Соединения и способы их применения
TN2015000396A1 (en) Antibody drug conjugates
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201591559A1 (ru) Терапевтические пептиды
EA201591925A1 (ru) Терапевтические композиции и их применение
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CY1121515T1 (el) Μεθοδοι και συνθεσεις για την επουλωση πληγων
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CY1120508T1 (el) Αναστολεις glyt1 για χρηση στη θεραπευτικη αγωγη αιματολογικων διαταραχων